HC Wainwright Has Lowered Expectations for Tyra Biosciences (NASDAQ:TYRA) Stock Price

Tyra Biosciences (NASDAQ:TYRA - Free Report) had its price target lowered by HC Wainwright from $32.00 to $30.00 in a report released on Monday,Benzinga reports. HC Wainwright currently has a buy rating on the stock.

Several other research analysts have also recently issued reports on the company. Wedbush reissued an "outperform" rating and issued a $28.00 target price on shares of Tyra Biosciences in a research report on Friday, October 25th. Piper Sandler began coverage on Tyra Biosciences in a research note on Thursday, August 15th. They issued an "overweight" rating and a $33.00 price objective on the stock. Bank of America raised Tyra Biosciences from a "neutral" rating to a "buy" rating and raised their price objective for the stock from $22.00 to $31.00 in a research note on Friday, October 18th. Finally, Oppenheimer raised their price objective on Tyra Biosciences from $25.00 to $33.00 and gave the stock an "outperform" rating in a research note on Thursday, September 19th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $31.00.

Tyra Biosciences Stock Up 0.7 %

NASDAQ:TYRA traded up $0.12 on Monday, hitting $16.23. The stock had a trading volume of 162,322 shares, compared to its average volume of 190,123. The stock has a market cap of $857.04 million, a price-to-earnings ratio of -10.08 and a beta of 1.08. The business's 50-day simple moving average is $21.73 and its two-hundred day simple moving average is $20.01. Tyra Biosciences has a 52-week low of $10.60 and a 52-week high of $29.60.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last announced its earnings results on Thursday, November 7th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by ($0.01). As a group, equities research analysts anticipate that Tyra Biosciences will post -1.53 EPS for the current year.

Insider Transactions at Tyra Biosciences

In related news, Director Nina S. Kjellson sold 11,078 shares of Tyra Biosciences stock in a transaction that occurred on Wednesday, October 30th. The stock was sold at an average price of $16.17, for a total transaction of $179,131.26. Following the sale, the director now owns 472,207 shares of the company's stock, valued at approximately $7,635,587.19. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, Director Nina S. Kjellson sold 11,078 shares of Tyra Biosciences stock in a transaction that occurred on Wednesday, October 30th. The stock was sold at an average price of $16.17, for a total transaction of $179,131.26. Following the sale, the director now owns 472,207 shares of the company's stock, valued at approximately $7,635,587.19. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Todd Harris sold 5,698 shares of Tyra Biosciences stock in a transaction that occurred on Thursday, September 19th. The shares were sold at an average price of $24.31, for a total value of $138,518.38. Following the sale, the chief executive officer now directly owns 1,496,729 shares in the company, valued at $36,385,481.99. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 101,050 shares of company stock valued at $2,235,492 over the last quarter. 15.40% of the stock is currently owned by company insiders.

Institutional Trading of Tyra Biosciences

Large investors have recently added to or reduced their stakes in the company. SG Americas Securities LLC bought a new stake in Tyra Biosciences in the 3rd quarter worth approximately $311,000. HighVista Strategies LLC bought a new stake in Tyra Biosciences in the 2nd quarter worth approximately $257,000. Quest Partners LLC bought a new stake in Tyra Biosciences in the 3rd quarter worth approximately $491,000. Rhumbline Advisers boosted its holdings in shares of Tyra Biosciences by 12.3% in the 2nd quarter. Rhumbline Advisers now owns 23,572 shares of the company's stock worth $377,000 after purchasing an additional 2,574 shares during the period. Finally, Bank of New York Mellon Corp boosted its holdings in shares of Tyra Biosciences by 32.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 58,087 shares of the company's stock worth $929,000 after purchasing an additional 14,352 shares during the period. Institutional investors own 84.14% of the company's stock.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.